Rockville-based MacroGenics Inc., which filed Wednesday for a $60 million initial public offering, revealed in its IPO paperwork it lost $3.7 million in the first half of 2013, on $22.9 million revenue.

For a clinical stage biotech like MacroGenics, posting a loss is not at all unexpected. Intrexon Corp., the last Washington-area biotech to go public, lost $81.9 million last year.

MacroGenics plans to use the proceeds from the planned offering to fund clinical trials for two cancer-targeting monoclonal antibodies, Margetuximab (MGAH22) and MGA271, as well as several other earlier stage assets. The company has a number of pharma partnerships in place, among them Servier, Gilead and Pfizer. The Maryland biotech actually posted a profit of $6.7 million in 2011 and $8.4 million in 2012, respectively, "due primarily to upfront fees paid by our collaborators," the company said in its S-1 filing.

It expects "that over the next several years we will increase our expenditures in research and development in connection with our ongoing activities with several clinical trials."